Musaffa Logo
Epigenomics AG ECX.DE

Last Updated: Jun 27, 12:00 AM·XDUS

ECX.DE Shariah Compliance

Screening Methodology: AAOIFI

As of July 2026, Epigenomics AG is classified as halal.

HALAL

Report Source: 2023 2nd Quarter Report

Epigenomics AG

Epigenomics AG. Stock Analysis ECX.DE

Germany Health Care Nano Cap Report:
Epigenomics AG is a molecular diagnostics company, which engages in the development and commercializing of proprietary products for the screening and diagnosis of cancer. The company is headquartered in Berlin, Berlin and currently employs 18 full-time employees. The company went IPO on 2004-07-19. The company develops and commercializes blood-based diagnostic products across multiple cancer indications. The firm's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. The company also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The firm is present in Europe and the United States.
Read More

Epigenomics AG (ECX.DE) Chart

Key Statistics of Epigenomics AG (ECX.DE)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

€0.52€0.70

Today's Open

€0.52

Volume

5061.00

P/E Ratio (TTM)

-

52 Week Range

€0.30€0.70

Market Cap

-

Avg. Volume

1072.56

Dividend Yield

-

Financial Metrics & Statements of Epigenomics AG (ECX.DE)

Super Investors Invested in Epigenomics AG (ECX.DE)

FAQ's for Epigenomics AG (ECX.DE)

  • As of July 2026, Epigenomics AG ECX.DE is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Epigenomics AG using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Epigenomics AG if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Epigenomics AG by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Epigenomics AG may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Epigenomics AG on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.